The Pharma’s Almanac editorial team is very excited to present our Q2 digital issue. This issue includes new content from our team and our colleagues at Nice Insight, as well as a large number of incredible subject matter experts from across the pharma/biopharma ecosystem, including drug discovery and development companies, life science industrials, technology providers, and contract development and manufacturing organizations. The diverse selection of topics touches on a huge spectrum of topics, united by the central thread of innovations that are ushering in the future of the industry.
Philipp Spycher, Ph.D. of Araris Biotech, discusses his company’s new peptide linker technology, which has been shown in preclinical studies to enable highly targeted delivery of payloads with minimal loss during circulation.
Pharma's Almanac Editor in Chief David Alvaro, Ph.D., discusses a recent study exploring the failures of adequate representation in the clinical trials leading to the approval of CAR-T cell therapy products.
In his M&A column in our Q2 issue, Nice Insight's Nigel Walker explores factors impacting demand for CDMO services, how they are changing the M&A market, and some CDMOs that might be on the block for acquisition.
Pharma's Almanac's David Alvaro discusses Mounjaro, Eli Lilly's exciting new first-in-class type 2 diabetes drug.
Pharma's Almanac's Danielle Alvarez discusses biotech IPOs thus far in 2022 and questions when we will see a return to past growth.
In this regulatory column, Pharma's Almanac's David Alvaro explores the recent FDA guidance on "Development of Non-Opioid Analgesics for Acute Pain."
Pharma's Almanac's Danielle Alvarez discusses non-fungible tokens (NFTs) and a range of their possible applications in pharma.
Nice Insight's Strategy Director Tonia Becker lays out a roadmap for improving the resilience of the pharma supply chain in the wake of the COVID-19 pandemic.
Nice Insight's Marc Technow discusses the special impacts the COVID-19 pandemic had on mental health.
The Pharma's Almanac editorial team shine a spotlight on 10 exciting biotechs.
Pharma's Almanac's Cynthia Challener provides a detailed overview of the next generation of cell therapies.
In this Pharma's Almanac roundtable, a panel of industry experts discusses the next hot orphan space or unmet medical need.
In this roundtable, a large number of SMEs explore the biggest challenges faced by the industry.
Pharma's Almanac's Cynthia Challener explores the potential of quantum computing to transform all aspects of pharma.
In this excerpt from Nice Insight's 2022 Active Pharmaceutical Ingredient (API) Market Report & CDMO Pricing Study, Research Director James Grote explores current trends in the small molecule API market.
In this extended Q&A, Jeff Elton, Ph.D., Chief Executive Officer of ConcertAI, discusses the promise of real-world data and artificial intelligence in clinical research and the role ConcertAI is taking as an accelerator of evidence generation.
Hui Chen, Ph.D., Vice President of Analytical & Quality Control and Gene Therapy at Porton Advanced, discusses the company’s unique analytical capabilities for supporting viral vector and plasmid DNA manufacturing.
In this Q&A, Amryt’s President Americas Sheila Frame discusses the company’s dedication to transforming the lives of patients with rare diseases, including acromegaly, epidermolysis bullosa, lipodystrophy and homozygous familial hypercholesterolemia.
Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics discuss the basis for selection of Lonza to meet Pionyr’s goals to rapidly develop a third lead candidate from the start and to scale-up manufacturing of two clinical-stage immuno-oncology treatments after tech transfer.
Mark Shlomchik, M.D., Ph.D., co-founder and Chief Scientific Officer at BlueSphere Bio, discusses how the company’s new platform technologies enable the rapid development of effective personalized T cell receptor (TCR) T cell therapies for the treatment of solid tumors.
Robert Foster, Pharm.D., Ph.D., CEO of Hepion Pharmaceuticals, discusses the history of cyclophilin inhibitors and Hepion's candidate drug, rencofilstat/CRV431.
Olon’s Senior Vice President of Research & Development Giorgio Bertolini, Ph.D., discusses the company's creation of a major new global research and development (R&D) hub at its headquarters in Rodano, Italy.
Evonik's Andrea Engel, Ph.D., and Philipp Heller, Ph.D.,m discuss the development of charge-altering releasable transporters (CARTs), polymeric delivery vehicles that capable of delivering many types of nucleic acids and potentially other negatively charged biomolecules that complement lipid nanoparticle delivery.
aCGT Vector is developing disruptive technology that is poised to transform the way CAR-T and other autologous cell therapies are manufactured, locating PODular “GMP-in-a-POD” distributed manufacturing systems in cancer centers of excellence.
RoosterBio is leveraging NFT technology as a means to build an engaged community of members who look to them for both regenerative medicine expertise and putting themselves ahead of the NFT curve.
Representatives from start-up development company Wheeler Bio and its digitalization partners, DataHow and Synthace, discuss how their collaboration will help Wheeler gain deeper insights into its processes more quickly and accelerate the time to IND for its customers.
Richter-Helm’s Kai Pohlmeyer, Ph.D., and Thilo Kamphausen, Ph.D., discuss the company’s upcoming expansion in Bovenau, Germany, how pDNA manufacturing is differentiated from more conventional biomanufacturing, and how to ensure and test for the highest level of quality.
OcuTerra Therapeutics, with their lead compound OTT166, is seeking to enable earlier and more patient-centric intervention for diabetic retinopathy.
Avid Bioservices' Atef Khezri and Chris Berger discuss how Avid's long quality and compliance track record and purpose-built viral vector manufacturing facility will extend Avid’s unparalleled dedication to quality into the cell and gene therapy sector.
Scorpion Biological Services' Director of Analytical Development Nick Raja, Ph.D., explains the process of bioanalytical development from inception through qualification and validation.
Anima Biotech's Yochi Slonim explains how Anima's unique technology can accelerate the discovery and development of small molecule drugs targeting mRNA translation, transport, and relocalization.
Phenotypeca's Keith Williams discusses how the company is combining breeding and rational engineering technologies to rapidly generate next-generation strains of Saccharomyces cerevisiae that optimize biomanufacturing, reducing cost and time to market for drug developers.
Jeff Tremain and Ania VanDyke discuss the new regulatory requirements for ophthalmic formulations designed for administration as eye drops and the importance of partnering with a full service provider experienced in meeting complex compliance requirements.
Vectron Biosolutions CEO Trond Erik Vee Aune discusses some of the primary challenges face in the manufacturing of biotherapeutics and explains how Vectron's E. coli technology can help developers overcome many of them.
BlueWillow Biologics Chief Executive Officer Chad Costley, M.D., discusses the historical development of mucosal and intranasal vaccines and their advantages over intramuscular delivery.
Daniel Joseph Price, Ph.D., Strategic Marketing Manager for the SAFC® portfolio of solid formulation excipients at MilliporeSigma, explains how the Developability Classification System is enabling the development of better excipients for poorly soluble compounds and simplifying the formulation process for these challenging APIs.
Citius Pharmaceuticals is developing novel medical solutions that address specialized needs for which no products are on the market, from a prescription hemorrhoid treatment to a solution for salvaging infected catheters
RoosterBio’s media platform for culturing mesenchymal stem cells (MSCs) reduces the time and cost limitations while generating billions of MSCs. Our Scientific Editor in Chief examines how this platform enables cell therapy companies to profitably bring their novel treatments to patients at a reasonable price.
Tim Schuetter, Site General Manager at AbbVie, discusses the unique challenges of ophthalmic ointment manufacture and the importance of experienced manufacturing partners with specialized capabilities in the aseptic processing of these unique products.
Prof. Dr. Ulrike Fiedler, Chief Commercial Officer at IDT Biologika, explains the drivers of IDT Biologika's recent notable investments in greater capacity and capabilities across the board, and what might be coming for the industry and the company in the near future.
Zachary Pitluk, Ph.D., Vice President, Life Sciences and Healthcare, explains how Paradigm4’s innovative technology is elevating companies to unique, first-in-class players and enhancing data cohesion.
Amy Sheng, Rob Burgess, and Lillith Elmore of Sino Biological discuss the company's extensive experience developing processes for the production of all types of antibodies and how it continues to invest in more technologys to meet the evolving needs of the marketplace.
Aniruddha Bose of MilliporeSigma examines how intensified bioprocessing technologies, together with software, automation, and analytics, will help advance the industry through its digital transformation.